
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 23, 2013

CORONADO BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35366
(Commission
File Number)

20-5157386
(IRS Employer
Identification No.)

24 New England Executive Park, Burlington, MA
(Address of Principal Executive Offices)

01803
(Zip Code)

Registrant's Telephone Number, Including Area Code: (781) 652-4500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 and incorporated herein by reference is a presentation that Coronado Biosciences, Inc. plans to use with various investors and analysts.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Presentation of December 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORONADO BIOSCIENCES, INC.

Date: December 24, 2013

/s/ Lucy Lu, M.D.

Lucy, Lu, M.D.

Executive Vice President and Chief Financial Officer

coronado

B I O S C I E N C E S

NASDAQ: CNDO

Lindsay A. Rosenwald, MD
Chairman, President and CEO

December 2013

Forward-Looking Statements

Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks include those set forth in our SEC filings including, in particular, risks relating to: our ability to attract, integrate and retain key personnel; the results of research and development activities; uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; our ability to successfully manufacture TSO in the US; dependence on third party manufacturers; and competition. We expressly disclaim any obligation or undertaking to update or revise any statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances after the date of this presentation.

Value Proposition

- » Experienced management team and board of directors
 - In both drug development and business development
 - Dedicated to maximizing **shareholder**value
- » Business development expertise
 - Products and technologies acquisitions and licensing
 - Investment and spin-out opportunities
 - Creative financing solutions
- » Two **biologic product candidates** in clinical stage development
 - Focused on autoimmune diseases and cancer immunotherapy
 - Strong proprietary position

Key Management and Board Members

Lindsay A. Rosenwald, MD
Chairman, President and CEO

- » Prolific and successful investor in the life sciences industry for over 20 years as Chairman of Paramount BioCapital
- » Co-Portfolio Manager and Partner of Opus Point Partners

Lucy Lu, MD
EVP & Chief Financial Officer

- » Senior Analyst at Citi Investment Research
- » Over 10 years of biotech equity research experience

George C. Avgerinos, PhD
Sr. VP, Biologics Operations

- » Divisional VP, Global Process and Manufacturing Sciences, Abbvie
- » Over 30 years experience in biopharmaceutical process development including Humira™ process and manufacturing

Kevin Horgan, MD
Chief Medical Officer

- » more than 25 years of academic and pharmaceutical experience
- » SVP and Chief Medical officer at Soligenix
- » Vice President of Clinical Immunology at Janssen Biotech

Michael S. Weiss
Co-Vice Chairman

- » Co-Portfolio Manager and Partner of Opus Point Partners, LLC (since 2009)
- » Executive Chairman, Interim CEO and President of TG Therapeutics
- » Chairman and CEO of Keryx Biopharmaceuticals

Eric K. Rowinsky, MD
Co-Vice Chairman

- » World renown oncologist, former CMO at ImClone, board of Biogen/Idec
- » Chief Medical Officer and Head of Research and Development; Executive Vice President at Stemline Therapeutics

Business Development Strategies

- » Products and technologies
 - We intend to pursue product and technology acquisitions and licenses.
- » Investment opportunities
 - We may make controlling and non-controlling investments in companies with proprietary products and/or technologies where we believe shareholder value will be enhanced, while preserving capital and strength of our balance sheet.
- » Spin-out opportunities
 - From time to time we may spin out new companies based on current and new technologies and products that we develop, license or acquire.

TSO: *Trichuris suis* ova (CNDO-201)

- » Porcine whipworm ova
 - Represents a novel approach to treating autoimmune diseases – the “Hygiene Hypothesis”
 - Natural immunomodulator -regulates T-Reg cells and inflammatory cytokines
- » Planned and ongoing studies in multiple autoimmune indications including psoriasis, autism, multiple sclerosis, and ulcerative colitis
- » Natural properties suggest strong potential for a safe profile
- » North and South America and Japanese rights for all indications

Benefits of *Trichuris suis ova* (TSO)

- » Does not multiply in human host
- » Colonization is self-limited in humans
- » No systemic phase
- » No direct transmission
- » Ova stable
- » Oral dosing; 1 tbsp solution taken once every 2 weeks
 - Clear, odorless, tasteless
 - Ova are Microscopic



TSO Phase 2 Crohn's Disease Studies

TRUST - I

- » 12 week study
 - TSO 7500 or placebo
 - N=250
 - Crohn's patients
 - CDAI = 220-450
 - The randomization was stratified by disease activity as measured by CDAI
- » Outcome – Did NOT meet overall primary endpoint of response

TRUST - II

- » 12 week, dose ranging study
 - TSO 250, 2500, 7500 or placebo
 - N=240
 - Crohn's patients
 - CDAI = 220-350
- » Outcome – Discontinued post 2nd Interim analysis

Select TSO Trials

Indication	Pre-Clinical	Phase 1	Phase 2a*	Phase 2	Phase 3	Design
Ulcerative Colitis						120 pt, DB, PC
Ulcerative Colitis (MOA)						18 pt, DB, PC
Multiple Sclerosis (US)						15 pt, SB
Multiple Sclerosis (EU)						50 pt, DB, PC
Autism						10 pt, DB, Cross
Autism			1H2014 (*)			60 pt, DB, PC
Psoriasis						20 pt, OL

*expected

OL = Open-Label DB = Double-Blind
SB= Single-Blind PC = Placebo-Controlled



* TSO Phase 2a studies being conducted as Investigator-Initiated Studies

Planned

Scientific Rationale for TSO for Autism

- » Numerous threads of evidence suggest that Autism is an immune mediated disorder linked to the hygiene hypothesis (HH)
 - Gene – environment mismatch is likely responsible for the dramatic increase in incidence
 - Increase parallels that of asthma and other HH conditions
- » Strong evidence for GI issues and immune dysregulation in Autism patients
 - Up to 70% of the patients have current or past GI issues, and endoscopy often shows low level inflammation in these patients
 - Abnormal cytokines, B cell and T cell subsets, and low levels of regulatory cytokines
 - Evidence of activation of the innate immune system in the CNS
 - Maternal autoimmune diagnosis is a recognized risk factor
- » Anecdotal evidence and the interim data from Dr. Hollander's study point to potential efficacy

Pilot Study of TSO in Autism

- » Ongoing double-blind, placebo-controlled, randomized cross-over study in 10 adult, high functioning autism patients at Montefiore Medical Center
- » In the first 5 patients that completed the study, there was a statistically significant separation from placebo in favor of TSO on three measures of disease that reflect a core feature of autism (the restrictive interests and repetitive behavior domain)
 - Montefiore-Einstein Rigidity Scale (MERS)
 - Repetitive Behavior Scale-Revised (RBS-R) Sameness Scale
 - Social Responsiveness Scale (SRS)-Repetitive Behaviors Scale
- » TSO is well tolerated
- » Final results are expected in mid 2014

TSO Intellectual Property

- » Three issued US patents entitled 'Use of Parasitic Biological Agents for Prevention and Control of Autoimmune Disease'directed to compositions, methods of producing compositions, and methods of autoimmune disease with helminths – exp. 12/2018
- » Five additional pending patents
 - 'Use of Parasitic Biological Agents for Disease Prevention and Control' - directed to the treatment of animals/man with a Th1 or Th2 mediated autoimmune disease – exp. 11/2023
 - 'Production of a Viable, Storable Worm Egg Suspension' - directed to a process for preparation of TSO using an acid wash - exp. 3/2028
 - 'Method for Characterizing the Biological Activity of Helminth Eggs, in particular *Trichuris Eggs*' – exp. 5/2029
 - 'Treatment with Helminths' directed to methods of treating obesity and IBS - exp. 10/2029
 - 'Compositions and Methods for Treating IBD' - directed to a method of treating IBD by contacting an isolated dendritic/macrophage cell with a helminth – exp. ~9/2032


** Expiration dates do not include any patent term extension*

CNDO-109: Activated Natural Killer Cells

- » NK cells represent the key component of the body's innate immune surveillance system
- » Proof of principle established in patients with high-risk refractory or relapsed acute myeloid leukemia (AML)
- » Activation with CNDO-109 does not require toxic cytokines or long-term culture/expansion, and does not change NK cell phenotypes
- » Preclinical activity demonstrated in multiple myeloma, breast cancer, prostate cancer and ovarian cancer

CNDO-109 Mechanism of Action

- » Activated *ex vivo* by tumor cell lysate (CNDO-109)
- » Effective from autologous or allogeneic NK cell source
- » Uniquely positioned in patients with “minimal residual disease”
- » Remains active after freeze/thaw



CNDO-109 Phase 1 Study in AML

- » Phase 1 investigator sponsored open-label trial
- » To determine the safety of infusion of allogeneic Tumor-activated NK (TaNK) cells after low dose radiotherapy plus chemotherapy in high-risk relapse or refractory AML patients
- » Enrolled 8 AML patients
 - 5 in Complete Remission at time of study entry
 - 1 patient in partial relapse (PR) at time of study entry
- » 3/5 experienced a longer CR than their previous CR, in addition PR patient achieved CR

Kottaridis, *et al.*, ASH 2011

CNDO-109 Clinical Development

- » Initiated Phase 1/2 allogeneic clinical trial for the treatment of relapsed AML
- » Future autologous studies in other tumor types are possible (e.g. multiple myeloma, breast, ovarian and prostate)

CNDO-109 Intellectual Property

- » Core patent - “Method for activating natural killer cells by tumor cell preparation *in vitro*”
 - Issued in U.S. - exp. 1/2029
 - Issued in Australia – exp. 3/2026
 - Pending in Europe, Canada, Japan and India
- » Patent pending - “Preserved Compositions of Activated NK Cells and Methods of Using the Same” – exp. 7/2030
- » Provisional application pending in the U.S. - “Compositions and Methods for Treating Viral Infections”

** Expiration dates do not include any patent term extension*

Financials

Listed on NASDAQ: CNDO

Market Cap *as of 12/20/2013* ~\$75M

Shares Outstanding 35.5M

- Additional 4.0 M options and warrants
- Additional 3.9 M restricted shares

Cash Position *as of 9/30/2013* \$106.3M

Total Debt *as of 9/30/2013* \$15.0M

Accounts Payable *as of 9/30/2013* \$1.1M

Working Capital *as of 9/30/2013* \$96.9M